Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17221287 | 0.91 | ROCK1 (0.47) | NR1H4ROCK1PDPK1GRM2 | |
| SCHEMBL29481438 | 0.91 | ROCK1 (0.47) | NR1H4ROCK1PDPK1GRM2 | |
| SCHEMBL29481424 | 0.91 | ROCK1 (0.47) | NR1H4ROCK1PDPK1GRM2 | |
| SCHEMBL20713785 | 0.89 | NR1H4 (0.39) | NR1H4ROCK1GRM2ACHECYP1A2 | |
| SCHEMBL23012707 | 0.85 | ROCK1 (0.44) | NR1H4ROCK1GRM2 | |
| SCHEMBL1438293 | 0.84 | PDPK1 (0.36) | NR1H4PDPK1GRM2 | |
| SCHEMBL29649948 | 0.84 | PDPK1 (0.36) | NR1H4PDPK1GRM2 | |
| SCHEMBL29508504 | 0.84 | PDPK1 (0.36) | NR1H4PDPK1GRM2 | |
| SCHEMBL3733168 | 0.81 | ROCK1 (0.38) | NR1H4ROCK1PDPK1GRM2 | |
| SCHEMBL8233620 | 0.80 | GABRG2 (0.39) | NR1H4PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | KLKB1, KLK1, KLK5 | NR1H4 3885/4885ROCK1 772/4885PDPK1 566/4885 |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | NR1H4 3885/4885ROCK1 772/4885PDPK1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.